Mersana Therapeutics
Biotechnology, 840 Memorial Dr, Cambridge, Massachusetts, 02139, United States, 51-200 Employees
Phone Number: 16*********
Who is MERSANA THERAPEUTICS
At Mersana, we have a passion for advancing therapies to make a significant impact in the lives of people living with cancer. Mersana Therapeutics is a clinical-stage biopharmaceutical co...
Read More
-
Headquarters: 840 Memorial Dr, Cambridge, Massachusetts, 02139, United States
-
Date Founded: 2001
-
Employees: 51-200
-
Revenue: $10 Million to $25 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
Does something look wrong? Fix it. | View contact records from MERSANA THERAPEUTICS
Mersana Therapeutics Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Mersana Therapeutics
Answer: Mersana Therapeutics's headquarters are located at 840 Memorial Dr, Cambridge, Massachusetts, 02139, United States
Answer: Mersana Therapeutics's phone number is 16*********
Answer: Mersana Therapeutics's official website is https://mersana.com
Answer: Mersana Therapeutics's revenue is $10 Million to $25 Million
Answer: Mersana Therapeutics's SIC: 2834
Answer: Mersana Therapeutics's NAICS: 325412
Answer: Mersana Therapeutics has 51-200 employees
Answer: Mersana Therapeutics is in Biotechnology
Answer: Mersana Therapeutics contact info: Phone number: 16********* Website: https://mersana.com
Answer: At Mersana, we have a passion for advancing therapies to make a significant impact in the lives of people living with cancer. Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options. The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms that are generating a pipeline of wholly-owned and partnered product candidates with the potential to treat a range of cancers. Its pipeline includes XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2).
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month